170 related articles for article (PubMed ID: 23217102)
1. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.
Triozzi PL; Achberger S; Aldrich W; Singh AD; Grane R; Borden EC
J Transl Med; 2012 Dec; 10():241. PubMed ID: 23217102
[TBL] [Abstract][Full Text] [Related]
2. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.
Achberger S; Aldrich W; Tubbs R; Crabb JW; Singh AD; Triozzi PL
Mol Immunol; 2014 Apr; 58(2):182-6. PubMed ID: 24370793
[TBL] [Abstract][Full Text] [Related]
3. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.
Brennecke S; Deichmann M; Naeher H; Kurzen H
Melanoma Res; 2005 Dec; 15(6):515-22. PubMed ID: 16314737
[TBL] [Abstract][Full Text] [Related]
4. Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma.
Triozzi PL; Achberger S; Aldrich W; Crabb JW; Saunthararajah Y; Singh AD
Clin Epigenetics; 2016; 8():80. PubMed ID: 27453764
[TBL] [Abstract][Full Text] [Related]
5. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes.
Binkley E; Triozzi PL; Rybicki L; Achberger S; Aldrich W; Singh A
Br J Ophthalmol; 2020 Apr; 104(4):524-528. PubMed ID: 31371315
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
7. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Kivelä T; Suciu S; Hansson J; Kruit WH; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
Eur J Cancer; 2003 May; 39(8):1115-20. PubMed ID: 12736111
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
Adam L; Black PC; Kassouf W; Eve B; McConkey D; Munsell MF; Benedict WF; Dinney CP
J Urol; 2007 May; 177(5):1900-6. PubMed ID: 17437845
[TBL] [Abstract][Full Text] [Related]
10. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
Mulder NH; Willemse PH; Schraffordt Koops H; de Vries EG; Sleijfer DT
Br J Cancer; 1990 Dec; 62(6):1006-7. PubMed ID: 2257203
[No Abstract] [Full Text] [Related]
11. A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
Gröhn P; Kumpulainen E; Nuortio L; Hakala T; Vuoristo MS; Korpela M; Heikkinen M; Salmi R; Jakobsson M; Numminen S
Eur J Cancer; 1992; 28(2-3):441-3. PubMed ID: 1591060
[TBL] [Abstract][Full Text] [Related]
12. Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells.
Joshi P; Kooshki M; Aldrich W; Varghai D; Zborowski M; Singh AD; Triozzi PL
Clin Exp Metastasis; 2016 Dec; 33(8):829-838. PubMed ID: 27565163
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM;
J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic role of miR-20a in breast cancer.
Luengo-Gil G; Gonzalez-Billalabeitia E; Perez-Henarejos SA; Navarro Manzano E; Chaves-Benito A; Garcia-Martinez E; Garcia-Garre E; Vicente V; Ayala de la Peña F
PLoS One; 2018; 13(4):e0194638. PubMed ID: 29617404
[TBL] [Abstract][Full Text] [Related]
15. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
Moschos SJ; Odoux C; Land SR; Agarwala S; Friedland D; Volker KM; Sidor C; Wong M; Kirkwood JM
Melanoma Res; 2007 Jun; 17(3):193-200. PubMed ID: 17505265
[TBL] [Abstract][Full Text] [Related]
16. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus.
Robak E; Kierstan M; Cebula B; Krawczynska A; Sysa-Jedrzejowska A; Wierzbowska A; Smolewski P; Robak T
Lupus; 2009 Apr; 18(4):332-41. PubMed ID: 19276301
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer.
Donnem T; Fenton CG; Lonvik K; Berg T; Eklo K; Andersen S; Stenvold H; Al-Shibli K; Al-Saad S; Bremnes RM; Busund LT
PLoS One; 2012; 7(1):e29671. PubMed ID: 22295063
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-199a-3p inhibits angiogenesis by targeting the VEGF/PI3K/AKT signalling pathway in an in vitro model of diabetic retinopathy.
Wang L; Liu WX; Huang XG
Exp Mol Pathol; 2020 Oct; 116():104488. PubMed ID: 32622012
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study.
Dithmar S; Rusciano D; Lynn MJ; Lawson DH; Armstrong CA; Grossniklaus HE
Arch Ophthalmol; 2000 Aug; 118(8):1085-9. PubMed ID: 10922203
[TBL] [Abstract][Full Text] [Related]
20. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ
J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
